Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes

IF 8.5 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Diabetology Pub Date : 2024-09-16 DOI:10.1186/s12933-024-02417-6

Jiwon Park, Hangyul Song, Shinje Moon, Yumin Kim, Sungsoo Cho, Kyungdo Han, Cheol-Young Park, Sung Woo Cho, Chang-Myung Oh

{"title":"Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes","authors":"Jiwon Park, Hangyul Song, Shinje Moon, Yumin Kim, Sungsoo Cho, Kyungdo Han, Cheol-Young Park, Sung Woo Cho, Chang-Myung Oh","doi":"10.1186/s12933-024-02417-6","DOIUrl":null,"url":null,"abstract":"Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease. This study aimed to investigate the effects of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, on the obese- and diabetes-related cardiomyopathy. We used db/db mice and high fat diet-streptozotocin induced diabetic mice to investigate the underlying mechanisms of fenofibrate’s beneficial effects on heart function. Fenofibrate reduced fibrosis, and lipid accumulation, and suppressed inflammatory and immunological responses in the heart via TNF signaling. In addition, we investigated the beneficial effects of fenofibrate on HF hospitalization. The Korean National Health Insurance database was used to identify 427,154 fenofibrate users and 427,154 non-users for comparison. During the 4.22-year follow-up, fenofibrate use significantly reduced the risk of HF hospitalization (hazard ratio, 0.907; 95% CI 0.824–0.998). The findings suggest that fenofibrate may be a useful therapeutic agent for obesity- and diabetes-related cardiomyopathy.","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Diabetology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12933-024-02417-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease. This study aimed to investigate the effects of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, on the obese- and diabetes-related cardiomyopathy. We used db/db mice and high fat diet-streptozotocin induced diabetic mice to investigate the underlying mechanisms of fenofibrate’s beneficial effects on heart function. Fenofibrate reduced fibrosis, and lipid accumulation, and suppressed inflammatory and immunological responses in the heart via TNF signaling. In addition, we investigated the beneficial effects of fenofibrate on HF hospitalization. The Korean National Health Insurance database was used to identify 427,154 fenofibrate users and 427,154 non-users for comparison. During the 4.22-year follow-up, fenofibrate use significantly reduced the risk of HF hospitalization (hazard ratio, 0.907; 95% CI 0.824–0.998). The findings suggest that fenofibrate may be a useful therapeutic agent for obesity- and diabetes-related cardiomyopathy.

查看原文本刊更多论文

非诺贝特对肥胖和糖尿病相关性心力衰竭的心脏代谢益处

心力衰竭（HF）是一种严重的常见病，影响着全球数百万人，而肥胖是糖尿病和心血管疾病等代谢紊乱的主要原因。本研究旨在探讨过氧化物酶体增殖激活受体α（PPARα）激动剂非诺贝特对肥胖和糖尿病相关心肌病的影响。我们利用db/db小鼠和高脂饮食-链脲佐菌素诱导的糖尿病小鼠来研究非诺贝特对心脏功能产生有益影响的内在机制。非诺贝特可减少纤维化和脂质积累，并通过 TNF 信号转导抑制心脏的炎症和免疫反应。此外，我们还研究了非诺贝特对高血压住院治疗的有益影响。我们利用韩国国民健康保险数据库确定了427154名非诺贝特使用者和427154名非使用者进行对比。在4.22年的随访期间，使用非诺贝特能显著降低高血压住院风险（危险比为0.907；95% CI为0.824-0.998）。研究结果表明，非诺贝特可能是肥胖和糖尿病相关心肌病的有效治疗药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Diabetology 医学-内分泌学与代谢

CiteScore

12.30

自引率

15.10%

发文量

240

审稿时长

1 months

期刊介绍： Cardiovascular Diabetology is a journal that welcomes manuscripts exploring various aspects of the relationship between diabetes, cardiovascular health, and the metabolic syndrome. We invite submissions related to clinical studies, genetic investigations, experimental research, pharmacological studies, epidemiological analyses, and molecular biology research in this field.